DEF: 89bio, Inc. Announces 2025 Annual Meeting of Stockholders and Executive Compensation Details

89bio, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on May 28, 2025, to vote on director elections, auditor ratification, and executive compensation.

Summary

• 89bio, Inc. is holding its 2025 Annual Meeting of Stockholders on May 28, 2025, virtually.
• Stockholders will vote on the election of three Class III directors, ratification of KPMG LLP as the independent auditor, and an advisory vote on executive compensation.
• The Board of Directors recommends voting for all director nominees and for Proposals 2 and 3.
• The record date for determining stockholders eligible to vote is April 3, 2025.
• The proxy materials are available online at www.proxyvote.com.
• The company's governance structure includes a classified board, supermajority voting requirements, and plurality voting for directors.
• The Board has determined that all directors, except for the CEO Rohan Palekar, are independent.
• The company's executive compensation program is designed to attract, retain, and reward executive officers to promote long-term success.
• In 2024, the company initiated two global Phase 3 trials for pegozafermin to treat MASH and completed enrollment in the ENTRUST SHTG Phase 3 trial.
• The company raised approximately $165 million in equity financings and increased its debt facility to $150 million.
• The CEO pay ratio for 2024 is approximately 19:1, with the CEO's annual total compensation at $7,619,426 and the median employee's at $396,532.
• The company has a clawback policy and prohibits hedging and pledging of company stock.

Sentiment

Score: 7

Explanation: The document presents a balanced view with positive developments in clinical trials and financing, but also acknowledges risks inherent in the biopharmaceutical industry and governance structure.

Positives

• The company is actively progressing its pegozafermin program with the initiation of two Phase 3 trials and completion of enrollment in another.
• The company successfully raised $165 million in equity financings and increased its debt facility, ensuring financial stability for ongoing programs.
• The company has a clawback policy and prohibits hedging and pledging of company stock, promoting responsible financial practices.
• The company received over 98% support for its say-on-pay proposal at its 2024 Annual Meeting of Stockholders, representing overall support of its executive compensation programs.

Risks

• The company faces extreme stock price and volume fluctuations that are often unrelated or disproportionate to its operating performance.
• The company's success is heavily dependent on the successful development and commercialization of pegozafermin.
• The company's governance structure includes supermajority voting requirements, which could make it difficult for stockholders to effect change.

Future Outlook

The company is focused on advancing the development of pegozafermin and scaling the organization to support late clinical stage activities and BLA preparedness.

Management Comments

• The Board believes our current governance structure enables the management team to act with deliberation and to focus on delivering long-term value to stockholders and protect minority investors from the interests of potentially short-sighted investors who may seek to act opportunistically and not in the best interests of the Company or stockholders generally.

Industry Context

The company operates in the biopharmaceutical industry, which is characterized by high risk, long development timelines, and significant regulatory hurdles. The company's focus on liver and cardiometabolic diseases aligns with growing market needs.

Comparison to Industry Standards

• The peer group used for executive compensation benchmarking includes companies like Akero Therapeutics, Madrigal Pharmaceuticals, and Viking Therapeutics, which are also focused on liver and cardiometabolic diseases.
• The company's executive compensation program aims to align with the 50th percentile for base salary and target annual cash incentive compensation and the 75th percentile for equity-based compensation compared to its peer group.
• The company's corporate governance practices, including the use of an independent chairman and all-independent committees, are consistent with industry best practices.

Management Changes

Related Party Transactions

• Melissa Zaharias, the spouse of Quoc Le-Nguyen (our Chief Technical Operations Officer), provided services to the Company during fiscal year 2024, receiving approximately $83,000 for quality assurance consulting services from January 1, 2024 through March 3, 2024.
• Effective March 4, 2024, Ms. Zaharias was hired as Senior Director, Chemistry, Manufacturing and Controls (CMC) Quality Assurance, with a compensation package including an annualized base salary and target bonus potential aggregating approximately $344,000.

Stakeholder Impact

• Stockholders will have the opportunity to vote on key decisions regarding the company's governance and executive compensation.
• Employees are impacted by the company's compensation policies and benefit programs.
• The company's success in developing and commercializing pegozafermin will benefit patients with liver and cardiometabolic diseases.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will continue to advance the development of pegozafermin and prepare for potential regulatory submissions.
• The Board will continue to evaluate the company's governance structure and compensation practices.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Director Election, Executive Compensation, KPMG, Pegozafermin, MASH, SHTG, Corporate Governance, Equity Financing, Stockholders